Article
Trypanosoma Cruzi Experimental Infection and COVID-19: Similar Cardiovascular Syndrome?
Registro en:
ABBAGLIATO, André Secundino; ROSSI, Maria Inês Doria; OLIVEIRA, Gabriel Melo de. Trypanosoma Cruzi Experimental Infection and COVID-19: Similar Cardiovascular Syndrome? American Journal of Biomedical Science & Research, v. 13, n. 1, p. 1-6, June 2021.
2642-1747
10.34297/AJBSR.2021.13.001832
Autor
Abbagliato, André Secundino
Rossi, Maria Inês Doria
Oliveira, Gabriel Melo de
Resumen
Dr. Carlos Chagas, in 1909, published his notable discovery, a new pathology denominated Chagas disease. He was able to identify: etiologic
agent, the protozoan Trypanosoma cruzi, its biological cycle and your pathogenesis: etiologic agent, the protozoan T. cruzi its biological cycle and
your pathogenesis. However, to date, there is still no vaccine or effective treatment for the symptomatic chronic phase. In 2019, a new Severe Acute
Respiratory Syndrome, promoted by a member of the Coronavirus family, emerged in Wuhan (China province), whose origin has not yet been totally
elucidate. SARS-Cov-2 or COVID-19 is characterize by high transmissibility and high morbidity. Thus, in 2020 it became a global pandemic. Highlights
into similarities between a neglected disease, which affects 40.000 new cases per year and intense research for a vaccine and treatment using
experimental models and severe COVID-19 infection, with millions of victims, by evolution to cardiovascular disturbance, mainly through its target
point to ACE2 enzyme. To compare acute T. cruzi experimental infection in mice, the cardiorenal axis involvement and suggest possible common
points to research about serious course of the COVID- 19 infection and cardiovascular involvement.